Alastair P Greystoke

12PUBLICATIONS
153CO-AUTHORS
Molecular targetsCancer geneticsNanomedicineCancer therapy (excl. chemotherapy and radiation therapy)Medical infection agents (incl. prions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (12)

|Sep 09, 2026
Ceralasertib plus durvalumab in Ras mutant and Ras wild type advanced non-small cell lung cancer: Two cohorts of the phase II platform National Lung Matrix Trial.

|Nov 08, 2025
Experimental Cancer Medicine Centre (ECMC) network proposal for a consensus gene panel for pan-cancer sequencing: a Delphi methodology.

Richard Phillips, Bristi Basu, Zohra Butt

|Aug 01, 2025
Dendrimer-Nanoparticle (DEP) Delivery of Topoisomerase I Inhibitor, SN38 (DEP-SN38): Safety, Tolerability, and Preliminary Efficacy Study in Patients With Advanced Solid Tumors.

Jia Liu, Anna R Minchom, Alastair Greystoke

|Jun 27, 2025
Defactinib with avutometinib in patients with solid tumors: the phase 1 FRAME trial.

Susana Banerjee, Matthew G Krebs, Alastair Greystoke

|Sep 04, 2024
Results From First-in-Human Phase I Dose-Escalation Study of a Novel Bicycle Toxin Conjugate Targeting EphA2 (BT5528) in Patients With Advanced Solid Tumors.

Babar Bashir, Judy S Wang, Gerald Falchook

|Aug 21, 2024
A gut microbiota rheostat forecasts responsiveness to PD-L1 and VEGF blockade in mesothelioma.

Min Zhang, Aleksandra Bzura, Essa Y Baitei

Pageof 2

Frequent Collaborators

2 joint publications

Hendrik-Tobias Arkenau

2 joint publications

Anthony M Joshua

2 joint publications

Juanita Lopez

2 joint publications

Bristi Basu